AIDX$0.228-2.98%
20/20 Biolabs, Inc.
Sector: Services-Testing LaboratoriesIndustry: Medical - Care FacilitiesCountry: USExchange: Nasdaq
Mkt Cap:$2.91M
Float & O/S:
Inst Own:
DilutionScan read 20 of 20/20 Biolabs, Inc.'s SEC filings and found 8 warrant series, 11 convertibles, 1 equity line, 2 S-1 registrations and 6 completed offerings on file for AIDX. The latest dilution event on file is an offering on Jun 16, 2026. Analysis updated Oct 6, 2026.
Signal8 Summary
AIDX
Unprofitable micro-cap with comfortable cash runway
Snapshot
AIDX is an unprofitable micro-cap clinical laboratory testing company with growing revenue. FY 2025 revenue was $2.0M, up 16.7% year-over-year, but the company posted a net loss of $3.7M.
What's Happening Right Now
- : The company highlighted themes from its investor webinar, focusing on positioning OneTest for Medicare reimbursement, enabling serial biomarker tracking, and noting strong Q2 revenue growth.
- : The State of Vermont selected the OneTest blood test to screen up to 4,500 firefighters in a twelve-month contract expected to generate approximately $500,000 in testing revenues.
- : 20/20 BioLabs reported Q1 2026 revenue of $353K, down from the prior year due to order timing, but strengthened its balance sheet with a $5M private placement bringing cash to $4.2M.
- : 20/20 BioLabs exclusively licensed a patented PSA Velocity algorithm from the University of South Carolina to help identify dangerous prostate tumors earlier.
